Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Childrens Oncology Group Randomized Trial Pediatric Oncology Group 9404 [Pediatric Oncology]

Conclusion Dexrazoxane was cardioprotective and did not compromise antitumor efficacy, did not increase the frequencies of toxicities, and was not associated with a significant increase in second malignancies with this doxorubicin-containing chemotherapy regimen. We recommend dexrazoxane as a cardioprotectant for children and adolescents who have malignancies treated with anthracyclines.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Chemotherapy, Chemotherapy, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Long Term Survival & Late Effects, Outcomes Research, Supportive Care Pediatric Oncology Source Type: research